Regeneron Pharmaceuticals Inc (NASDAQ:REGN), the biopharmaceutical company reported Q3 results below analysts' expectations and lowered the top end of its guidance for full-year U.S. net sales of its Eylea treatment for diabetic macular edema. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is trading in a 52-week range of $257.69 to $410.18. Net income declined to $79.7 million, or $0.70 per diluted share, from $141.3 million, or $1.25 per diluted share, a year earlier. Excluding one-time items, its earnings per diluted share rose to $2.52 in the latest quarter from $2.40 a year earlier, but analysts polled by Capital IQ were looking for $2.61.Total revenue climbed 22% to $725.8 million but missed analysts' consensus estimate of $733.1 million. Net sales in the U.S. of Eylea jumped 23% to $445 million while collaboration revenue rose to $269 million from $223 million a year earlier, boosted primarily by an increase in its net profit from commercialization of EYLEA outside the U.S."We believe EYLEA is positioned for continued strong growth given recent approvals in macular edema following retinal vein occlusion and diabetic macular edema (DME) as well as top-line results of the NIH-sponsored DRCR Protocol T DME study, in which EYLEA showed significant gains in visual acuity compared to both alternative anti-VEGF therapies," said Leonard S. Schleifer, president and CEO. However, the company lowered the top end of its full-year forecast for Eylea U.S. net product sales, now seeing a range of $1.7 billion to $1.74 billion, versus its prior guidance for $1.7 billion to $1.8 billion.Endurance International Group Hldgs Inc (NASDAQ:EIGI), which provides cloud-based platform solutions designed to help small and medium-sized businesses succeed online, reported a Q3 net loss that narrowed from a year prior. Net loss attributable to Endurance International Group Holdings, Inc. was $7.9 million, or $0.06 per diluted share, compared to a net loss of $27.0 million, or $0.28 per diluted share, for Q3 2013. If comparable, the Street view was for a gain of $0.24 per share on a non-GAAP basis and a loss of $0.05 per share on a GAAP basis, according to Capital IQ.GAAP revenue was $160.2 million, an increase of approximately 21% compared to $132.9 million in Q3 2013. Adjusted revenue was $164.9 million, an increase of approximately 23% compared to $134.2 million in Q3 2013. Analyst revenue estimates were $162 million. For the full fiscal year, Endurance expects adjusted revenue of from $648 million to $650 million, revised from $639 million to $643 million. The Street is at $633 million. Endurance International Group Hldgs Inc (NASDAQ:EIGI) trades in a 52-week range of $10.41 to $17.00.Office Depot Inc (NASDAQ:ODP), an office products provider, announced Q3 results that beat the Street view on EPS and total revenues. The company reported Q3 adjusted EPS of $0.10, up from $0.05 in Q3 2013 and beating analyst estimates of $0.09. Total revenues of $4.06 billion were up from $2.61 billion in Q3 2013 and topping analyst projections of $4.05 billion for the quarter. In North America, same-store sales declined 3% versus last year, primarily due to lower transaction counts.The company has raised its 2014 outlook for adjusted operating income to a range of $255 million to $265 million from previous guidance of not less than $200 million. Office Depot Inc (NASDAQ:ODP) has provided a preliminary estimate for 2015 adjusted operating income of approximately $475 million, driven largely by realization merger integration synergies. Shares of ODP are at $5.07 within a 52-week range of $3.84 - $5.91.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
